IMO the probability of standard of care for TLX591 is high so I don’t even consider a salvageable product.
Pluvicto has already demonstrated this to a certain extent. And I interpreted CB to mean that 591 was better than Pluvicto but it wasn’t clear.
The main issue for 591 therapeutics is manufacturing and logistics as I understand - hence the investment in Telix’s own facility which has progressed beautifully.
Ann: JP Morgan Healthcare Conference and Trading Update, page-116
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.98 |
Change
-0.490(2.09%) |
Mkt cap ! $7.691B | |||
| Open | High | Low | Value | Volume |
| $23.25 | $23.36 | $22.78 | $32.40M | 1.409M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $22.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.99 | 421 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |